BindingDB logo
myBDB logout

31 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26258602 39 Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.EBI Pfizer Inc
26218650 41 Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.EBI Korea Research Institute of Chemical Technology
25897973 29 Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors.EBI Takeda Pharmaceutical Co., Ltd
24900877 107 Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.EBI Merck Research Laboratories
24618302 49 Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.EBI Merck Research Laboratories
24670009 65 Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.EBI Amgen Inc
23871442 88 Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.EBI Pfizer Inc
23810496 31 Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.EBI Korea Research Institute of Chemical Technology
23541669 92 Identification and design of a novel series of MGAT2 inhibitors.EBI AstraZeneca
23317570 42 Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.EBI Merck Research Laboratories
23116186 68 Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).EBI AstraZeneca
22263872 15 Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.EBI Abbott Laboratories
24900485 13 Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides.EBI TBA
24900321 10 Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.EBI TBA
22217874 49 Design and synthesis of potent carboxylic acid DGAT1 inhibitors with high cell permeability.EBI Prosidion Ltd
21413799 63 Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.EBI Hoffmann-La Roche Inc
29986142 21 Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).EBI TBA
31930920 69 The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.EBI Terns Pharmaceuticals
26561979 42 Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.EBI Merck & Co., Inc.
29456796 51 Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.EBI GlaxoSmithKline
29699923 47 Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.EBI WuXi AppTec (Shanghai) Co. Ltd
28820267 4 Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts.EBI Merck & Co. Inc
28498655 13 Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans.EBI Novartis Institutes for BioMedical Research
19334715 10 Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease.BDB CNRS
16325401 25 Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.BDB Vernalis (R&D) Ltd
11708910 42 Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action.BDB National Institutes of Health